Millipore Sigma Vibrant Logo

504839 (R)-CPP - CAS 126453-07-4 - Calbiochem

504839
価格&在庫状況を照会

概要

Replacement Information

主要スペック表

CAS #Empirical Formula
126453-07-4C₈H₁₇N₂O₅P

価格&在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
5.04839.0001
在庫状況検索中…
現在国内在庫なし
現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      ガラスビン 10 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示 
      値引
      ()
       
      弊社照会
      Description
      OverviewA highly potent antagonist slightly selective for NR2A over other subtype NMDA receptors (Ki = 0.041, 0.27, 0.63 and 1.99 µM for NMDA subtypes NR2A, NR2B, NR2C, and NR2D, respectively). Commonly used for various research in brain functions and disorders that neurotransmissions via NMDA receptors are involved.
      Catalogue Number504839
      Brand Family Calbiochem®
      Synonyms(R)-3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid
      References
      ReferencesMurphy, R., et al. 2012. Psychopharmacol. 219, 401.
      Paoletti, P., et al. 2007. Curr. Opin. Pharmacol. 7, 47.
      Feng, B., et al. 2004. Br. J. Pharmacol. 141, 508.
      Lowe, A., et al. 1990. Neurosci. Lett. 113, 315.
      Product Information
      CAS number126453-07-4
      FormOff-white solid
      Hill FormulaC₈H₁₇N₂O₅P
      Chemical formulaC₈H₁₇N₂O₅P
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetNMDA receptors
      Primary Target K<sub>i</sub>0.041, 0.27, 0.63 and 1.99 →M for NMDA subtypes NR2A, NR2B, NR2C, and NR2D, respectively.
      Purity≥98% by NMR
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      5.04839.0001 04055977243567

      Documentation

      (R)-CPP - CAS 126453-07-4 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート((M)SDS) 

      参考資料

      参考資料の概要
      Murphy, R., et al. 2012. Psychopharmacol. 219, 401.
      Paoletti, P., et al. 2007. Curr. Opin. Pharmacol. 7, 47.
      Feng, B., et al. 2004. Br. J. Pharmacol. 141, 508.
      Lowe, A., et al. 1990. Neurosci. Lett. 113, 315.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision26-July-2013 JSW
      Synonyms(R)-3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid
      DescriptionA highly potent antagonist slightly selective for NR2A over other subtype NMDA receptors (Ki = 0.041, 0.27, 0.63 and 1.99 µM for NMDA subtypes NR2A, NR2B, NR2C, and NR2D, respectively). Commonly used for various research in brain functions and disorders that neurotransmissions via NMDA receptors are involved.
      FormOff-white solid
      CAS number126453-07-4
      Chemical formulaC₈H₁₇N₂O₅P
      Structure formulaStructure formula
      Purity≥98% by NMR
      SolubilityH₂O (100 mM)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesMurphy, R., et al. 2012. Psychopharmacol. 219, 401.
      Paoletti, P., et al. 2007. Curr. Opin. Pharmacol. 7, 47.
      Feng, B., et al. 2004. Br. J. Pharmacol. 141, 508.
      Lowe, A., et al. 1990. Neurosci. Lett. 113, 315.